Overview

Clinical Trial for Zebinix (Eslicarbazepine Acetate) in Healthy Korean and Caucasian Adult

Status:
Completed
Trial end date:
2019-12-16
Target enrollment:
Participant gender:
Summary
A dose randomized, double-blind, placebo controlled, single and multiple dosing, dose-escalation phase I clinical trial to investigate the safety, tolerability and pharmacokinetic characteristics of Zebinix (Eslicarbazepine acetate) after oral administration in healthy Korean and Caucasian adult subjects
Phase:
Phase 1
Details
Lead Sponsor:
Whanin Pharmaceutical Company
Treatments:
Eslicarbazepine acetate